Ebola and Marburg
Outbreaks can kill 25 to 90 per cent of those infected. No cure exists and treatment is currently mainly symptomatic. MSF has intervened in almost all reported outbreaks over the past years. The 2014-2015 Ebola epidemic in West Africa was unprecedented: 67 times the size of the largest previously recorded outbreak, it reached urban areas, and killed more than 11,300 people. Hundreds of health workers died, decimating the already-struggling healthcare systems of Liberia, Guinea and Sierra Leone.
Once a case of Marburg or Ebola is confirmed, a swift response is vital. The needs of patients and affected communities must remain at the heart of the response, which can be defined by six main pillars : care and isolation of patients; tracing and follow up of patient contacts; raising community awareness of the disease such as how to prevent it and where to seek care; conducting safe burials; proactively detecting new cases; and supporting existing health structures.
Diagnosing Ebola or Marburg is difficult because early symptoms, such as fever and sore throat, are common to many illnesses. A patient presenting early symptoms should be cared for and isolated to prevent further risk of infection to relatives and care takers. Public health professionals should be notified and a laboratory test must be carried out to confirm a diagnosis. Such tests are an extreme biohazard risk and should be conducted under maximum biological containment conditions.
There is no specific treatment for Ebola or Marburg haemorrhagic fevers. Standard care is limited to supportive therapy, such as hydrating the patient, nutritional support, providing fever and pain medication, and drugs to reduce vomiting and diarrhoea. Other diseases the patient may have such as malaria or sepsis, should also be treated. Patients should be isolated to prevent infecting others. Psychological support should be provided to help patients and families.
Human to human transmission occurs through contact with bodily fluids of an infected person or through surfaces contaminated with these fluids. Infection control in health centres is vital to reduce risks for other patients, for caregivers and health workers. Those caring for infected patients must wear personal protective equipment (PPE). Direct contact with the deceased can transmit the virus, so burial teams also use PPE, and safe burials must be carried out in a dignified manner for family members.
In the wake of the 2014-2015 West Africa Ebola epidemic, an investigational vaccine was developed that can help control an outbreak. The vaccine is currently being trialled in an Ebola outbreak in the DRC, as part of the overall strategy to control the epidemic. MSF is vaccinated Ebola frontline workers and patient contacts in remote communities in Bikoro, Equateur Province. Participation is voluntary and the vaccine is free.
Survivors often face stigma and are ostracised from their communities. This, and the trauma of having lived through such a deadly disease, often requires counselling. People may experience ongoing physical side-effects, such as joint pain, headaches and eye problems that require treatment and follow up. MSF established Ebola survivor centres in three worst-affected countries after the West Africa epidemic.
MSF Ebola treatment centre opens in Mangina, North Kivu
New Ebola outbreak declared in North Kivu
Ministry of Health declares Ebola epidemic over
“Congolese health workers have shown an amazing commitment to fighting Ebola”
MSF hands over Ebola response activities in DRC
Ebola update June 2018
“I will start today from zero”
Fighting Ebola on the ground, a race against time
MSF starts Ebola vaccination targeting remote communities
Research & Publications
MSF Field Research
We produce important research based on our field experience. So far, we have published articles in over 100 peer-reviewed journals. These articles have often changed clinical practice and have been used for humanitarian advocacy. All of these articles can be found on our dedicated Field Research website.Visit site